Acétate de desmopressine CAS:16789-98-3

Usage : L'acétate de desmopressine est utilisé pour l'énurésie nocturne, troubles de la coagulation et diabète insipide.

La description:

Desmopressine (noms commerciaux: Davp, DesmoFusion, Minirine, Fondant Minirin, Octim, Cher) est un substitut synthétique à la vasopressine, l'hormone qui réduit la production d'urine. Il peut être pris par voie nasale, par voie intraveineuse, ou sous forme de comprimé oral ou sublingual. Les médecins prescrivent le plus souvent de la desmopressine pour le traitement du diabète insipide, bedwetting, or nocturia.

Application :

Doctors prescribe desmopressin frequently for treatment of nocturnal enuresis (bedwetting). It is usually prescribed in the form of oral desmopressin acetate, Davp. Patients taking DDAVP are 4.5 times more likely to sleep without disruption compared with placebo.

Desmopressin can be used to promote the release of von Willebrand factor (with subsequent increase in factor VIII survival secondary to vWF complexing) in patients with coagulation disorders such as von Willebrand disease, mild hemophilia A (factor VIII deficiency), and thrombocytopenia. It can be used with uremic induced platelet dysfunction. It is not effective in the treatment of hemophilia B (factor IX deficiency), severe hemophilia A, or von Willebrand.

Desmopressin is used in the treatment of central diabetes insipidus (DI), to replace endogenous ADH that is missing in the central nervous system type of this disorder (decreased production of ADH from the posterior pituitary). It is also used in the diagnostic workup for diabetes insipidus, in order to distinguish central from nephrogenic DI.